Ralfinamide
Based on 1 publication(s) in Google Scholar
Ralfinamide (FCE-26742A) is an orally available Na+ blocker derived from α-aminoamide, with function of suppressing pain.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.21%
- CAS No.: 133865-88-0
- Formule: C17H19FN2O2
- Masse moléculaire:302.35
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Anti-COVID-19 Compound Library
HY-L052
-
Orally Active Compound Library
HY-L061
-
Human Metabolite Library
HY-L123
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Ion Channel Compound Library
HY-L166
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
Clinical Compound Library Plus
HY-L026P
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Membrane Transporter/Ion Channel Compound Library
HY-L011
-
Clinical Compound Library
HY-L026
-
Drug Repurposing Compound Library
HY-L035
Publications Citing Use of MedChemExpress (MCE) Ralfinamide
More
Activité biologique
Na+channel[1]
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:81 adult male Sprague–Dawley male rats (260–460 g)[1]
-
Dosage:80 mg/kg (7 days preoperatively), 30 mg/kg, 60 mg/kg (postoperative)
-
Administration:Oral gavage; twice daily; until postoperative day 42
-
Result:Suppressed neuropathic pain.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 133865-88-0
-
Appearance Solid
-
Masse moléculaire 302.35
-
Formule C17H19FN2O2
-
Color White to off-white
-
SMILES
C[C@H](NCC1=CC=C(OCC2=CC=CC=C2F)C=C1)C(N)=O
-
Synonyms
FCE-26742A
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Acta Pharmacol Sin
Inhibition of Nav1.7 channel by a novel blocker QLS-81 for alleviation of neuropathic pain. [Abstract]2021 Aug;42(8):1235-1247. PMID: 34103689
Solvant et solubilité
DMSO : ≥ 125 mg/mL (413.43 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureté et documentation
-
Fiche technique (271 KB)
-
SDS (479 KB)
- English - EN (479 KB)
- Français - FR (479 KB)
- Deutsch - DE (479 KB)
- Norwegian - NO (479 KB)
- Español - ES (479 KB)
- Swedish - SV (479 KB)
- Italian - IT (479 KB)
- Korean - KR (479 KB)
- Portuguese - PT (479 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Zhang SH, et al. Ralfinamide administered orally before hindpaw neurectomy or postoperatively provided long-lasting suppression of spontaneous neuropathic pain-related behavior in the rat. Pain. 2008 Oct 15;139(2):293-305. [Content Brief]
[2]. Liang X, et al. Effects of ralfinamide in models of nerve injury and chemotherapy-induced neuropathic pain. Eur J Pharmacol. 2018 Mar 15;823:27-34. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.3074 mL | 16.5372 mL | 33.0744 mL | 82.6859 mL |
| 5 mM | 0.6615 mL | 3.3074 mL | 6.6149 mL | 16.5372 mL | |
| 10 mM | 0.3307 mL | 1.6537 mL | 3.3074 mL | 8.2686 mL | |
| 15 mM | 0.2205 mL | 1.1025 mL | 2.2050 mL | 5.5124 mL | |
| 20 mM | 0.1654 mL | 0.8269 mL | 1.6537 mL | 4.1343 mL | |
| 25 mM | 0.1323 mL | 0.6615 mL | 1.3230 mL | 3.3074 mL | |
| 30 mM | 0.1102 mL | 0.5512 mL | 1.1025 mL | 2.7562 mL | |
| 40 mM | 0.0827 mL | 0.4134 mL | 0.8269 mL | 2.0671 mL | |
| 50 mM | 0.0661 mL | 0.3307 mL | 0.6615 mL | 1.6537 mL | |
| 60 mM | 0.0551 mL | 0.2756 mL | 0.5512 mL | 1.3781 mL | |
| 80 mM | 0.0413 mL | 0.2067 mL | 0.4134 mL | 1.0336 mL | |
| 100 mM | 0.0331 mL | 0.1654 mL | 0.3307 mL | 0.8269 mL |
Ralfinamide Related Classifications
HY-101437 Related Classifications
Powered by Bioz